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Introduction:  Discogenic  lumbosciatica  is a common  disorder  in patients  between  30 and  40  years  old.
Because  of  the  frequency  and socio-professional  impact  of  this  entity,  it represents  a  real  public health
problem.  DiscoGel® is  a class  III medical  device  used  for nucleolysis  to  avoid discectomy.  The  goal  of
this  study  was  to evaluate  the effectiveness  of this  treatment  in  patients  with  discogenic  lumbosciatica
following  unsuccessful  conservative  medical  treatment.
Materials  and  methods:  This  is a retrospective,  single-center  study  including  25  patients  who  were  treated
with DiscoGel® between  2010  and  2011  at Niort  Hospital,  France.  The  severity  of  lumbar  and  radicular
pain  was  assessed  by a verbal  numeric  scale  (VNS)  and patient  satisfaction.  Patients  were classiﬁed  as
successes  or failures.
Results: Treatment  was found  to  reduce  the  severity  of  lumbar  pain  in  73% and  of  radicular  pain  in 80%  of
patients  in  the  success  group.  Treatment  was a  failure  in  64%  of patients.  A comparison  of the  two  groups
showed  that  a preoperative  MODIC  2  MRI  signal  of the  adjacent  vertebral  end  plate  was  signiﬁcantly
associated  with  treatment  failure  (Chi2 =  8572,  P < 0.01).
Discussion: The  VNS  for  lumbar  pain  and  radicular  pain  decreased  in 42% and  50%  of  patients  respectively
after  the  use  of  DiscoGel®. In our  series,  DiscoGel® treatment  was  unsuccessful  for discogenic  lumbosci-
atica  in  16  patients.  These  results  do  not  support  others  in  the  literature.  A lack  of statistical  power  could
partly  explain  these  results.  The  most  important  result  of  this  study  is  found  in the  subgroup  analysis
which  suggests  that  indications  for DiscoGel® treatment  could  be modiﬁed  in  the  future  in relation  to
preoperative  imaging  data.
Level  of evidence:  4.
© 2015  Published  by Elsevier  Masson  SAS.. Introduction
Common discogenic lumbosciatica is frequent in patients
etween 30 and 40 years old. Between 13% and 40% of the general
opulation will experience an episode of sciatica during his/her life
ue to discoradicular conﬂict. Because of its frequency and socio-
rofessional impact of this entity, it is a public health issue.
Percutaneous intradiscal techniques have been developed to
rovide treatment for discogenic lumbosciatica that is more effec-
ive than epidural inﬁltrations and less invasive than surgery. These
echniques result in nucleolysis with a physicochemical action and
ucleotomy with a physical action [1–3].
 DiscoGel® Gelscom 8, avenue de Dubna ZAC CITIS F-14 200
érouville-Saint-Clair.
∗ Corresponding author.
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877-0568/© 2015 Published by Elsevier Masson SAS.DiscoGel® is a class III intradiscal medical device composed of
geliﬁed ethanol associated with tungsten in suspension for nucle-
olysis. It is injected into the nucleus pulposus to reduce intradiscal
pressure. The presence of cellulose, which is a gelling agent, limits
the risk of epidural leaks that may  occur with pure ethanol. The
tungsten particles are used to control progression of the gel in the
disc and through any annular ﬁssures by ﬂuroscopic control. The
mechanism of action of DiscoGel® is based on several hypotheses:
• decreasing intradiscal pressure because of the dehydration
caused by injection of the product to decrease pain;
• lytic action on new nerve growth in the disc [4];
• necrotic action of alcohol on the nucleus pulposus [5].In 2007, Théron deﬁned the indications for DiscoGel® use in
his study of 202 cases [6]. For this author, DiscoGel® is an alter-
native to surgical treatment of radicular pain from contained or
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Table 1
Characteristics of the study population.
Total 25 patients, 9 women 16 men
Age 19–58 years old; mean age = 38.4
Mean pretreatment DRAD
Daily activities 71%
Activités professionnelles 66%
Mean pretreatment lumbar VNS 5.17
Mean pretreatment radicular VNS 6.87
Topography of lumbosciatica 12 L5, 13 S1
Medical history of inﬁltration 5 foraminal inﬁltrations, 1 epidural
inﬁltration
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•Interval between symptoms and
treatment with DiscoGel®
1 month–24 months mean 7.8 months
ncontained herniated discs at the cervical or lumbar levels, that
ave been present for more than 3 months, are resistant to medi-
al treatment with no neurological complications, and which have
een conﬁrmed by imaging techniques.
Twenty-eight patients in our center were treated with
iscoGel®. The goal was to evaluate the efﬁcacy of treatment of
umbar radicular pain as well as to compare the success and failure
reatment groups to identify any possible factors of failure.
. Materials and methods
Twenty-eight patients, aged 19 to 58 were treated with
iscoGel® between 2010 and 2011 by the same operator in the
ame center (Niort Hospital, France).
The initial population included 10 women and 18 men
resenting with clinical lumbosciatica due to median, para-
edian or foraminal subligamentous herniated discs on
maging.
Inclusion criteria were a clinical picture of discal lumbosciatica
hat was resistant to appropriate conservative medical treatment
nd conﬁrmed by imaging. Exclusion criteria were a history of
urgery of the spine at the involved levels and/or imaging results
hat did not support the clinical results, the presence of a hernia-
ed disc excluded on imaging, involvement of several levels and/or
ncomplete data collection.
The severity of lumbar and radicular pain was  evaluated by a
erbal numeric scale (VNS, 0 = no pain; 10 = maximum pain) before
reatment and at the postoperative consultation between D30–D45
fter injection of DiscoGel® to deﬁne the variation in the VNS as a
esult of treatment.
Patients were contacted by telephone to determine their level
f satisfaction with treatment. The patient was asked to rate the
utcome of treatment as poor/mediocre/satisfactory/very satis-
actory/excellent; and in case of failure to know if additional
reatment had been necessary. Seven of the 28 patients could
ot be reached by telephone, and these data were obtained from
he elements in the medical ﬁle during the different consulta-
ions. Three ﬁles were excluded from analysis due to lack of
ata.
The standardized DRAD questionnaire (Dallas pain self-
valuation [7]) was used to evaluate the repercussions of
umbosciatica on daily and professional activities before and after
iscoGel® treatment.
The characteristics of the study population are presented in
able 1.
Patients were classiﬁed into 2 groups:
in the success group if the VNS decreased by >50% and the patient
was satisﬁed;
in the failure group if the VNS decreased by ≤50% and/or the
patient was dissatisﬁed.Fig. 1. (Ph Brunner): DiscoGel® injection.
Satisfaction with DiscoGel® treatment was  classiﬁed as:
• poor;
• mediocre;
• average;
• good;
• very good;
• excellent.
Patients who responded poor, mediocre or average were consid-
ered to be dissatisﬁed with treatment while those who responded
good, very good or excellent were considered to be satisﬁed.
Treatment was considered to have failed in the following situa-
tions:
• decrease in VNS < 50%;
• patients who underwent a secondary procedure (inﬁltration or
surgery);
• patients who classiﬁed the results of treatment as poor, mediocre
or average even if they did not undergo a secondary procedure.
The study population was  divided into two  groups based on the
results: patients for whom the DiscoGel® procedure was success-
ful and those for whom it was a failure. These two  groups were
analyzed and compared to identify any prognostic factors of failure.
The DiscoGel® injection protocol was the following
(Figs. 1 and 2):
• outpatient procedure;
• in the surgical block under strictly aseptic conditions;
• under local and neuroleptic anesthesia;
• with the patient lying on the stomach;
• under ﬂuoroscopic control;
• 18G needle;
• slow percutaneous injection of DiscoGel® 0.1 mL/30 seconds;
• progression of the product controlled by ﬂuoroscopy;
• a single operator;
• with three hours of postoperative surveillance.
3. Results
There were no complications during the procedure, and no leak-
ing of the product. Fifteen of the 25 patients (60%) seen at follow
up were on sick leave at the ﬁrst postoperative consultation due to
lumbosciatica pain.
Treatment with DiscoGel® was  considered to be a failure in 16
patients, or 64% of the population. Fourteen of these 16 failures
underwent secondary treatment. A total of 56% of the population
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Fig. 2. (Ph Brunner): mode of injection.
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DiscoGel® is a new minimally invasive therapeutic technique
for the treatment of discogenic lumbosciatia and an alternative to
invasive surgery in case of unsuccessful medical treatment.
Table 2
Characteristics of 2 subgroups.
Satisﬁed group
n = 9
Dissatisﬁed group
n = 16
Population 1 woman, 8 men  8 women, 8 men
Mean age 38.2 38.5
VNS before Lumbar VNS = 4.88
Radicular VNS = 6.66
Lumbar VNS = 5.21
Radicular VNS = 7.00
VNS after Lumbar VNS = 1.33 or a Lumbar VNS = 4.07 or aFig. 3. Results of treatment in the study population.
nderwent either foraminal inﬁltration, a cure for a herniated disc
r arthrodesis. Two out of 16 failures did not undergo secondary
reatment but rated the DiscoGel® treatment as mediocre or poor,
espectively.
The VNS for lumbar pain in the 25 patients who  were evaluated
n the study went from 5.17 to 3.00 or a decrease of 42%. The VNS
or radicular pain went from 6.87 to 3.43 or a decrease of 50%. Nev-
rtheless, the decrease in VNS was still ≤50%, the threshold chosen
or the treatment to be considered a success (Figs. 3 and 4).
Two groups can be identiﬁed in this study:a group of 9 patients in whom DiscoGel® was a success because
the lumbar and radicular VNS decreased by >50% AND the patient
was satisﬁed with treatment;
0
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before treatment
aer treatment
42% Decrease
50% Decrease
Tota l Popula on 
ig. 4. Variation in lumbar and radicular VNS before and after treatment for the
ntire study population.Fig. 5. Secondary treatments in the failure group.
• a group of 16 patients in whom DiscoGel® treatment was a failure
because the lumbar and radicular VNS decreased by ≤50% and/or
the patient stated that s/he was  dissatisﬁed.
In the group in which treatment failed 12/16 patients underwent
secondary surgery (Fig. 5.pdf). The characteristics of the two groups
are presented in Table 2.
In the satisﬁed group, the decrease in VNS for lumbar pain was
73% and for radicular pain was  80% compared to the dissatisﬁed
group in which the lumbar VNS decreased by 21% and the radicular
VNA by 26% (Fig. 6).
There were more men  in the success group, but this differ-
ence was  not signiﬁcant. On the other hand, a signiﬁcant number
of patients had a MODIC 2 sign in the failure group (Chi2 = 8.572,
P < 0.01). In other words, a disc with fatty degeneration was  associ-
ated with failure of DiscoGel® treatment. We did not ﬁnd any other
signiﬁcant factors to explain our failures.
4. Discussion73% decrease
Radicular VNS = 1.33 or a
80% decrease
21% decrease
Radicular VNS = 5.21 or a
26% decrease
Levels of lumbosciatica 5 L5
4 S1
8 L5
8 S1
MODIC 0 = 3 patients
1 = 6 patients
2 = 0 patients
0 = 2 patients
1 = 4 patients
2 = 10 patients
PFIRMANN 1 = 1 patient
2 = 1 patient
3 = 5 patients
4 = 2 patients
1 = 2 patients
2 = 1 patient
3 = 6 patients
4 = 5 patients
Discal narrowing None or less than 50% = 9
>50% = 0
None or less than
50% = 15
>50% = 1
Interval pain-treatment 9.3 months 8 months
DRAD daily activities
Pretreatment 65.3% 73.4%
Post-treatment 12% 62.3%
DRAD professional 85% 85%
Post treatment 10% 75%
Sick leave 44% 69%
Data in bold correspond to signiﬁcant differences.
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Fig. 6. Decrease in VNS in the success and failure groups.
Initial studies performed by Theron and De Seze found a success
ate of 91% and 75% with DiscoGel® [6,8]. Different studies have also
eported that the severity of lumbar and radicular pain decreased
y 80 to 85% with chemopapaïne [9–13] and by approximately 70%
ith replacement techniques [2,3].
In the success group the severity of lumbar and radicular pain
mproved by approximately 73% and 80% respectively, which cor-
esponds to the results of other studies in the literature. Moreover,
n previous studies patients eligible for DiscoGel® treatment have
een shown to have the following characteristics: men  with a nar-
ow lumbar canal, injury at L4-L5 and at only one level, with no pain
uring coughing, no narrowing of the disc space and symptoms for
ess than 1 year. Our success group corresponds to these eligibility
riteria because it included mostly men  who presented with lum-
osciatica that had been present for less than a year, involving a
ingle level. The mean period of time between pain and treatment
as 9 months in the success group and 8 months in the failure
roup; these results are fairly similar to those in the literature (4
onths for Theron et al. and 14 months for De Seze et al.).
On the other hand, the global analysis of our series does not sup-
ort the results in the literature because our failure rate was 64%.
hese results can be explained by the small size of the study result-
ng in a methodological weakness and a lack of statistical power.
he high rate of failures may  also be explained by the procedure
tself, which was not associated in this study with an injection of
ortisone as in the study by Theron et al. [6].
However, despite the small size of the study it seems clear
hat there is a correlation between the preoperative MODIC 1 MRI
[ Surgery & Research 101 (2015) 623–626
signal and treatment efﬁcacy. In our study, the presence of fatty
disc degeneration, presenting as a preoperative MODIC 2 MRI  sig-
nal was signiﬁcantly associated with failure. None of the existing
studies have taken into account this factor, which our results seem
to indicate is a potential prognostic parameter of treatment failure.
Treatment with DiscoGel® is being evaluated and is an alternative
to invasive procedures, which is why it is so important to determine
its speciﬁc ﬁeld of action.
5. Conclusion
DiscoGel® is an effective treatment for discogenic lumbosciat-
ica. The high rate of failures in our study was  signiﬁcantly related
to the presence of peridiscal fatty degeneration (MODIC 2). Further
studies are therefore needed to conﬁrm this hypothesis in a larger
group and to conﬁrm this feature as a potential prognostic factor
of treatment failure.
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